Amneal Pharmaceuticals LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amneal Pharmaceuticals LLC - overview
Established
2002
Location
Bridgewater, NJ-New Jersey, US
Primary Industry
Pharmaceuticals
About
Founded in 2002 and based in New Jersey, US, Amneal Pharmaceuticals, LLC develops, manufactures and distributes generic pharmaceuticals.
Current Investors
TPG, Fidelity Investments, Tarsadia Investments
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.amneal.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Amneal Pharmaceuticals LLC - timeline of key events
Amneal Pharmaceuticals LLC - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 511,502,000 | 596,049,000 | 860,469,000 | 824,429,000 | - | 1,662,991,000 | 1,626,373,000 | 1,992,523,000 | 2,093,669,000 | 2,212,304,000 | - | - | - |
| % Revenue Growth (YoY) | - | 16.5% | 44.4% | (4.2%) | (100.0%) | - | (2.2%) | 22.5% | 5.1% | 5.7% | - | - | - |
| EBITDA (USD) | 29,619,000 | 122,842,000 | 138,205,000 | (405,834,000) | - | 123,589,000 | 1,424,000 | 335,220,000 | 395,325,000 | 153,842,000 | - | - | - |
| Operating Income (USD) | (6,387,000) | 88,816,000 | 69,568,000 | (494,182,000) | - | (19,673,000) | (248,682,000) | 91,155,000 | 152,716,000 | (94,928,000) | - | - | - |
| Operating Margin | (1.2%) | 14.9% | 8.1% | (59.9%) | - | (1.2%) | (15.3%) | 4.6% | 7.3% | (4.3%) | - | - | - |
| % EBITDA Margin | 5.8% | 20.6% | 16.1% | (49.2%) | - | 7.4% | 0.1% | 16.8% | 18.9% | 7.0% | - | - | - |
| NET Income (USD) | 101,259,000 | 57,353,000 | 38,997,000 | (472,031,000) | - | (201,303,000) | (603,573,000) | 68,578,000 | 20,170,000 | (254,789,000) | - | - | - |
| % Net Margin | 19.8% | 9.6% | 4.5% | (57.3%) | - | (12.1%) | (37.1%) | 3.4% | 1.0% | (11.5%) | - | - | - |
Amneal Pharmaceuticals LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Kashiv BioSciences, LLC | - | ||||||||
| N/A | Completed | 10049 Sandmeyer Lane | - | ||||||||
| Add-on | Announced | Saol Therapeutics’ Baclofen Franchise | - | ||||||||
| Add-on | Completed | Puniska Healthcare Private Limited | - | ||||||||
| Add-on | Completed | Kashiv Specialty Pharmaceuticals, Inc. | - |
Displaying 1 - 5 of 9
Amneal Pharmaceuticals LLC - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.